|
1
|
Miyazono K, Kamiya Y and Morikawa M: Bone
morphogenetic protein receptors and signal transduction. J Biochem.
147:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wozney JM, Rosen V, Celeste AJ, Mitsock
LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators
of bone formation: molecular clones and activities. Science.
242:1528–1534. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Attisano L and Wrana JL: Signal
transduction by the TGF-beta superfamily. Science. 296:1646–1647.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee J, Son MJ, Woolard K, Donin NM, Li A,
Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al:
Epigenetic-mediated dysfunction of the bone morphogenetic protein
pathway inhibits differentiation of glioblastoma-initiating cells.
Cancer Cell. 13:69–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varga AC and Wrana JL: The disparate role
of BMP in stem cell biology. Oncogene. 24:5713–5721. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farnsworth RH, Karnezis T, Shayan R,
Matsumoto M, Nowell CJ, Achen MG and Stacker SA: A role for bone
morphogenetic protein-4 in lymph node vascular remodeling and
primary tumor growth. Cancer Res. 71:6547–6557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katzenellenbogen BS and Katzenellenbogen
JA: Estrogen receptor transcription and transactivation: Estrogen
receptor alpha and estrogen receptor beta: regulation by selective
estrogen receptor modulators and importance in breast cancer.
Breast Cancer Res. 2:335–344. 2000. View
Article : Google Scholar
|
|
8
|
Glidewell-Kenney C, Weiss J, Lee EJ,
Pillai S, Ishikawa T, Ariazi EA and Jameson JL: ERE-independent
ERalpha target genes differentially expressed in human breast
tumors. Mol Cell Endocrinol. 245:53–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holmes KA, Hurtado A, Brown GD, Launchbury
R, Ross-Innes CS, Hadfield J, Odom DT and Carroll JS:
Transducin-like enhancer protein 1 mediates estrogen receptor
binding and transcriptional activity in breast cancer cells. Proc
Natl Acad Sci USA. 109:2748–2753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vasudevan N, Kow LM and Pfaff DW: Early
membrane estrogenic effects required for full expression of slower
genomic actions in a nerve cell line. Proc Natl Acad Sci USA.
98:12267–12271. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baselga J, Semiglazov V, van Dam P,
Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R,
Bianchi G, et al: Phase II randomized study of neoadjuvant
everolimus plus letrozole compared with placebo plus letrozole in
patients with estrogen receptor-positive breast cancer. J Clin
Oncol. 27:2630–2637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edwards DP: Regulation of signal
transduction pathways by estrogen and progesterone. Annu Rev
Physiol. 67:335–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu H, Qiu J, Li N, Chen T and Cao X:
Human phosphatidylethanolamine-binding protein 4 promotes
transactivation of estrogen receptor alpha (ERalpha) in human
cancer cells by inhibiting proteasome-dependent ERalpha degradation
via association with Src. J Biol Chem. 285:21934–21942. 2010.
View Article : Google Scholar
|
|
14
|
Thomas C and Gustafsson JÅ: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herynk MH and Fuqua SA: Estrogen receptor
mutations in human disease. Endocr Rev. 25:869–898. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, Zhang X, Shen P, Loggie BW, Chang
Y and Deuel TF: Identification, cloning, and expression of human
estrogen receptor-alpha36, a novel variant of human estrogen
receptor-alpha66. Biochem Biophys Res Commun. 336:1023–1027. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller TW, Balko JM and Arteaga CL:
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast
cancer. J Clin Oncol. 29:4452–4461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ho CC and Bernard DJ: Bone morphogenetic
protein 2 acts via inhibitor of DNA binding proteins to
synergistically regulate follicle-stimulating hormone β
transcription with activin A. Endocrinology. 151:3445–3453.
2010.PubMed/NCBI
|
|
20
|
ten Dijke P, Korchynskyi O,
Valdimarsdottir G and Goumans MJ: Controlling cell fate by bone
morphogenetic protein receptors. Mol Cell Endocrinol. 211:105–113.
2003.PubMed/NCBI
|
|
21
|
Wang Z, Zhang X, Shen P, Loggie BW, Chang
Y and Deuel TF: A variant of estrogen receptor-{alpha},
hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent
membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA.
103:9063–9068. 2006.
|
|
22
|
Lin SL, Yan LY, Zhang XT, et al:
ERalpha-36, a variant of ER-alpha, promotes tamoxifen agonist
action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt
pathways. PLoS One. 5:e90132010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kipp JL, Kilen SM, Woodruff TK and Mayo
KE: Activin regulates estrogen receptor gene expression in the
mouse ovary. J Biol Chem. 282:36755–36765. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J,
Wang T, Fan Z, Fan T, Lin B, Wang Z and Xie Y: Expression of
ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and
resistance to tamoxifen treatment in breast cancer. J Clin Oncol.
27:3423–3429. 2009.
|
|
25
|
Lee LM, Cao J, Deng H, Chen P, Gatalica Z
and Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed
in ER-positive and -negative human breast carcinomas. Anticancer
Res. 28:479–483. 2008.PubMed/NCBI
|
|
26
|
Wu L, Wu Y, Gathings B, Wan M, Li X,
Grizzle W, Liu Z, Lu C, Mao Z and Cao X: Smad4 as a transcription
corepressor for estrogen receptor alpha. J Biol Chem.
278:15192–15200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumoto Y, Otsuka F, Takano M, Mukai T,
Yamanaka R, Takeda M, Miyoshi T, Inagaki K, Sada KE and Makino H:
Estrogen and glucocorticoid regulate osteoblast differentiation
through the interaction of bone morphogenetic protein-2 and tumor
necrosis factor-alpha in C2C12 cells. Mol Cell Endocrinol.
325:118–127. 2010. View Article : Google Scholar
|
|
28
|
Oreffo RO, Kusec V, Romberg S and Triffitt
JT: Human bone marrow osteoprogenitors express estrogen
receptor-alpha and bone morphogenetic proteins 2 and 4 mRNA during
osteoblastic differentiation. J Cell Biochem. 75:382–392. 1999.
View Article : Google Scholar
|
|
29
|
Zhang M, Wang Q, Yuan W, Yang S, Wang X,
Yan JD, Du J, Yin J, Gao SY, Sun BC and Zhu TH: Epigenetic
regulation of bone morphogenetic protein-6 gene expression in
breast cancer cells. J Steroid Biochem Mol Biol. 105:91–97. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamamoto T, Saatcioglu F and Matsuda T:
Cross-talk between bone morphogenic proteins and estrogen receptor
signaling. Endocrinology. 143:2635–2642. 2002. View Article : Google Scholar
|
